SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.81 Billion KRW | 32.86% |
| 2022 | -36.95 Billion KRW | 41.04% |
| 2021 | -62.67 Billion KRW | 1.7% |
| 2020 | -63.76 Billion KRW | -1026.11% |
| 2019 | 6.88 Billion KRW | 431.7% |
| 2018 | -2.07 Billion KRW | 72.47% |
| 2017 | -7.53 Billion KRW | 65.12% |
| 2016 | -21.61 Billion KRW | -2073.96% |
| 2015 | -994.38 Million KRW | 95.81% |
| 2014 | -23.74 Billion KRW | -28.45% |
| 2013 | -18.48 Billion KRW | -490.27% |
| 2012 | -3.13 Billion KRW | -79.19% |
| 2011 | -1.74 Billion KRW | -92.89% |
| 2010 | -906.23 Million KRW | -168.84% |
| 2009 | 1.31 Billion KRW | 107.58% |
| 2008 | 634.2 Million KRW | 126.91% |
| 2007 | -2.35 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.8 Billion KRW | 60.45% |
| 2024 Q2 | -10.27 Billion KRW | -113.65% |
| 2023 Q3 | -6.24 Billion KRW | -73.39% |
| 2023 Q4 | -12.16 Billion KRW | -94.81% |
| 2023 Q1 | -389.92 Million KRW | 97.77% |
| 2023 FY | -24.81 Billion KRW | 32.86% |
| 2023 Q2 | -3.6 Billion KRW | -823.38% |
| 2022 FY | -36.95 Billion KRW | 41.04% |
| 2022 Q1 | -2.59 Billion KRW | 80.63% |
| 2022 Q2 | -11.26 Billion KRW | -334.51% |
| 2022 Q3 | -3.04 Billion KRW | 72.95% |
| 2022 Q4 | -17.49 Billion KRW | -473.92% |
| 2021 Q3 | -6.7 Billion KRW | -7.11% |
| 2021 Q1 | -13.99 Billion KRW | 32.96% |
| 2021 FY | -62.67 Billion KRW | 1.7% |
| 2021 Q2 | -6.26 Billion KRW | 55.25% |
| 2021 Q4 | -13.38 Billion KRW | -99.56% |
| 2020 Q2 | -7.42 Billion KRW | 41.65% |
| 2020 Q4 | -20.87 Billion KRW | -1940.85% |
| 2020 FY | -63.76 Billion KRW | -1026.11% |
| 2020 Q1 | -12.72 Billion KRW | 0.0% |
| 2020 Q3 | 1.13 Billion KRW | 115.28% |
| 2019 Q2 | -189.77 Million KRW | -103.64% |
| 2019 Q1 | 5.21 Billion KRW | 207.95% |
| 2019 FY | 6.88 Billion KRW | 431.7% |
| 2019 Q3 | -6.34 Billion KRW | -3242.3% |
| 2018 Q4 | -4.83 Billion KRW | -772.61% |
| 2018 Q2 | 2.02 Billion KRW | 14734.5% |
| 2018 FY | -2.07 Billion KRW | 72.47% |
| 2018 Q1 | 13.63 Million KRW | 101.92% |
| 2018 Q3 | 718.14 Million KRW | -64.5% |
| 2017 Q3 | -2.54 Billion KRW | -34.7% |
| 2017 Q2 | -1.88 Billion KRW | 21.41% |
| 2017 Q1 | -2.4 Billion KRW | 78.76% |
| 2017 FY | -7.53 Billion KRW | 65.12% |
| 2017 Q4 | -710.24 Million KRW | 72.06% |
| 2016 Q4 | -11.3 Billion KRW | -151.59% |
| 2016 FY | -21.61 Billion KRW | -2073.96% |
| 2016 Q3 | -4.49 Billion KRW | -29.44% |
| 2016 Q2 | -3.47 Billion KRW | -47.77% |
| 2016 Q1 | -2.34 Billion KRW | -22.98% |
| 2015 Q1 | 205.7 Million KRW | 101.06% |
| 2015 Q2 | 5.14 Billion KRW | 2402.9% |
| 2015 Q3 | -4.43 Billion KRW | -186.18% |
| 2015 Q4 | -1.91 Billion KRW | 56.95% |
| 2015 FY | -994.38 Million KRW | 95.81% |
| 2014 Q4 | -19.4 Billion KRW | -1311.55% |
| 2014 Q3 | -1.37 Billion KRW | 38.4% |
| 2014 Q2 | -2.23 Billion KRW | -205.28% |
| 2014 Q1 | -731.16 Million KRW | 95.95% |
| 2014 FY | -23.74 Billion KRW | -28.45% |
| 2013 Q2 | 80.48 Million KRW | -82.78% |
| 2013 Q3 | -972.92 Million KRW | -1308.88% |
| 2013 Q4 | -18.06 Billion KRW | -1756.66% |
| 2013 Q1 | 467.48 Million KRW | 113.65% |
| 2013 FY | -18.48 Billion KRW | -490.27% |
| 2012 Q2 | 140.05 Million KRW | -47.32% |
| 2012 Q1 | 265.84 Million KRW | 134.13% |
| 2012 Q3 | -112.4 Million KRW | -180.26% |
| 2012 Q4 | -3.42 Billion KRW | -2947.74% |
| 2012 FY | -3.13 Billion KRW | -79.19% |
| 2011 FY | -1.74 Billion KRW | -92.89% |
| 2011 Q3 | -1.43 Billion KRW | -884.98% |
| 2011 Q4 | -778.89 Million KRW | 45.6% |
| 2011 Q1 | 280.32 Million KRW | 116.49% |
| 2011 Q2 | 182.4 Million KRW | -34.93% |
| 2010 Q3 | 179.69 Million KRW | -27.91% |
| 2010 FY | -906.23 Million KRW | -168.84% |
| 2010 Q2 | 249.27 Million KRW | -31.58% |
| 2010 Q1 | 364.31 Million KRW | -16.88% |
| 2010 Q4 | -1.69 Billion KRW | -1045.79% |
| 2009 Q2 | -195.09 Million KRW | -144.08% |
| 2009 Q3 | 630.77 Million KRW | 423.32% |
| 2009 Q1 | 442.55 Million KRW | 6321.78% |
| 2009 FY | 1.31 Billion KRW | 107.58% |
| 2009 Q4 | 438.27 Million KRW | -30.52% |
| 2008 Q1 | 282.11 Million KRW | 139.3% |
| 2008 Q2 | 298.87 Million KRW | 5.94% |
| 2008 FY | 634.2 Million KRW | 126.91% |
| 2008 Q3 | 60.32 Million KRW | -79.82% |
| 2008 Q4 | -7.11 Million KRW | -111.79% |
| 2007 Q3 | -2.27 Billion KRW | -655.2% |
| 2007 Q2 | 409.59 Million KRW | 81.69% |
| 2007 Q4 | -717.82 Million KRW | 68.43% |
| 2007 FY | -2.35 Billion KRW | 0.0% |
| 2007 Q1 | 225.44 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -245.528% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 142.787% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 58.36% |
| HANDOK Inc. | -28.79 Billion KRW | 13.84% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -194.848% |
| Yuhan Corporation | 93.5 Billion KRW | 126.534% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 323.08% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 116.968% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 807.176% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -889.941% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -1096.389% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -448.352% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 211.101% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -245.528% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -18.486% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 792.421% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 79.021% |
| JW Holdings Corporation | 19.02 Billion KRW | 230.409% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 68.564% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 111.675% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 167.048% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 56.717% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 505.309% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1591.52% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 595.77% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -245.528% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 167.122% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 122.253% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 167.048% |
| Yuhan Corporation | 93.5 Billion KRW | 126.534% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -52.692% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -540.22% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 505.476% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 167.048% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 231.24% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 151.411% |
| CKD Bio Corp. | -24.19 Billion KRW | -2.561% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 203.742% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 190.428% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 183.334% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 56.717% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 152.783% |
| Boryung Corporation | 40.2 Billion KRW | 161.717% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 20.803% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -889.941% |
| JW Lifescience Corporation | 28.14 Billion KRW | 188.161% |